Efficacy of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a pre-specified single-arm analysis from a randomized controlled trial.
Das Sambit, Das Bijay Ketan, Sahoo Devadarshini et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the effects of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) over 12 months. In a pre-specified single-arm analysis from a randomized controlled trial, significant reductions in hepatic steatosis (CAP: 316.7 to 245.7 dB/m) and liver stiffness (LSM: 8.59 to 7.28 kPa) were observed, both with p < 0.001.
Key findings
- Hepatic steatosis decreased significantly from 316.7 to 245.7 dB/m (mean change -71.02 dB/m, p < 0.001).
- Liver stiffness as a fibrosis surrogate reduced from 8.59 to 7.28 kPa (mean change -1.31 kPa, p < 0.001).
- Improvements were noted in glycaemic control, body weight, and liver function markers.
Why it matters
The findings suggest that dapagliflozin may effectively improve liver health in patients with type 2 diabetes and MASLD, highlighting its potential role in managing metabolic liver disease.
What to keep in mind
The study's single-arm design, open-label methodology, and relatively small sample size limit the generalizability of the findings.